Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy
Adoptive Immunotherapy for Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Xiangling He
- Phone Number: +86 13873102615
- Email: hexiangl@163.com
Study Contact Backup
- Name: Keke Chen
- Phone Number: +86 13974931408
- Email: chenkeke1982@126.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410005
- Recruiting
- Hunan Provincial People's Hospital
-
Contact:
- Xiangling He
- Phone Number: +86 13873102615
- Email: hexiangl@163.com
-
Contact:
- Keke Chen
- Phone Number: +86 13974931408
- Email: chenkeke1982@126.com
-
Principal Investigator:
- Xiangling He
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
For children CD19 positive B cell leukemia:
- All subjects must personally sign and date the Informed Consent before initiating any study specific procedures or activities;
- All subjects must be able to comply with all the scheduled procedures in the study;
- CD19-positive B-cell leukemia with histology or cytology confirmed recurrence after treatment; or progression during treatment; or after first line treatment getting a MRD negative, 2 times of MRD show>0.01% but without bone marrow morphology recurrence;
- At least one measurable lesion;
- Aged <18 years; or diagnosised at the age of less than 18 and relapsed within three years, determined by the investigator;
- Expected survival ≥12 weeks;
- Eastern cooperative oncology group(ECOG) performance status of≤2;
- Before CD19-TriCAR-T/SILK cell infusion, systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks;
- All other treatment induced adverse events must have been resolved to ≤grade 1;
For children CD19 positive B cell lymphoma:
- All subjects must personally sign and date the Informed Consent before initiating any study specific procedures or activities;
- All subjects must be able to comply with all the scheduled procedures in the study;
- CD19-positive B-cell lymphoma with histology or cytology confirmed recurrence after treatment,defined as one or more of the following: disease progression during standard therapy;recurrence after termination of treatment;relapse after autologous hematopoietic stem cell transplantation;not suitable for stem cell transplantation or abandon stem cell transplantation due to conditional restrictions;
- At least one measurable lesion;
- Aged <18 years; or diagnosised at the age of less than 18 and relapsed within three years, determined by the investigator;
- Expected survival ≥12 weeks;
- Eastern cooperative oncology group(ECOG) performance status of≤2;
- Before CD19-TriCAR-T/SILK cell infusion, systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks;
- All other treatment induced adverse events must have been resolved to ≤grade 1;
Exclusion Criteria:
- Presence of fungal, bacterial, viral, or other infection that is uncontrolled or requiring iv antimicrobials for management. (Simple UTI and uncomplicated bacterial pharyngitis are permitted if responding to active treatment);
- Patients with symptomatic central nervous system metastasis, intracranial metastasis, and cancer cells found in cerebrospinal fluid are not recommended to participate in this study. Symptom free or post-treatment stable disease or disappearance of lesions should not be excluded. The specific selection is ultimately determined by the investigator;
- Lactating women or women of childbearing age who plan to conceive during the time period;
- Active infection with hepatitis B (HBsAG positive) or hepatitis C virus (anti-HCV positive);
- Known history of infection with HIV;
- Subjects need systematic usage of corticosteroid;
- Subjects need systematic usage of immunosuppressive drug;
- Planed operation, history of other related disease, or any other related laboratory tests restrict patients for the study;
- Other reasons the investigator consider the patient may not be suitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: CD19-TriCAR-T/NK(SILK)
CD19-TriCAR-T/SILK cells will be administered intravenously
|
A conditioning chemotherapy regimen of fludarabine and cyclophosphamide may be administered, followed by a single infusion of CD19-TriCAR-T cells or 4 repeat infusions of CD19-TriCAR-SILK cells.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
safty (Incidence of treatment-related adverse events as assessed by CTCAE v4.03)
Time Frame: 24 monthes
|
Incidence of treatment-related adverse events as assessed by CTCAE v4.03
|
24 monthes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Complete response rate[CR] (Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma)
Time Frame: 24 monthes
|
Complete response rate per the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma
|
24 monthes
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Partial response rate [PR] (Partial response rate per the revised International Working Group (IWG) Response Criteria)
Time Frame: 24 monthes
|
Partial response rate per the revised International Working Group (IWG) Response Criteria
|
24 monthes
|
|
Duration of Response (The time from response to relapse or progression)
Time Frame: 24 monthes
|
The time from response to relapse or progression
|
24 monthes
|
|
Progression Free Survival (The time from the first day of treatment to the date on which disease progresses)
Time Frame: 24 monthes
|
The time from the first day of treatment to the date on which disease progresses
|
24 monthes
|
|
Overall Survival (The number of patient alive, with or without signs of cancer)
Time Frame: 24 monthes
|
The number of patient alive, with or without signs of cancer
|
24 monthes
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Xiangling He, Hunan Provincial People's Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- T2018-14
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.